Drug Database · Clinicians

Cefotaxime

Brands (51) Haxim, Cefogram, Ceforin…Show all

US brand (reference label): CLAFORAN; not a Philippine-registered brand.

Antibacterial (cephalosporin); Antibacterial (third-generation cephalosporin)l; and others PH FDA category

Rx · Prescription drug72 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 434fb630-c8d6-4583-b3ee-8e4ba6552c3d, version date August 14, 2026 (CLAFORAN · SteriMax Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Treatment CLAFORAN is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Treatment CLAFORAN is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli, Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae, Proteus mirabilis, Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa).

(2) Genitourinary infections. Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis, Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Proteus mirabilis, Proteus vulgaris *, Providencia stuartii, Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa).

Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including penicillinase producing strains. (3) Gynecologic infections, including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis, Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli, Proteus mirabilis, Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *).

CLAFORAN, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli, Klebsiella species, and Serratia marcescens, Staphylococcus aureus and Streptococcus species (including S. pneumonia).

(5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non- penicillinase producing), Staphylococcus epidermidis, Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli, Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis, Proteus vulgaris *, Morganella morganii, Providencia rettgeri *, Pseudomonas species, Serratia marcescens, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli, Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*.

(7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections, e.g., meningitis and ventriculitis, caused by Neisseria meningitidis, Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae * and Escherichia coli *.

(*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., E. faecalis) and Pseudomonas species are resistant to cefotaxime sodium in vitro, CLAFORAN has been used successfully in treating patients with infections caused by susceptible organisms.

Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to CLAFORAN. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.

In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, CLAFORAN may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient’s condition.

Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if CLAFORAN is used concomitantly with an aminoglycoside.

Prevention The administration of CLAFORAN preoperatively reduces the incidence of certain infections in patients undergoing surgical procedures (e.g., abdominal or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or potentially contaminated. In patients undergoing cesarean section, intraoperative (after clamping the umbilical cord) and postoperative use of CLAFORAN may also reduce the incidence of certain postoperative infections.

See DOSAGE AND ADMINISTRATION section. Effective use for elective surgery depends on the time of administration. To achieve effective tissue levels, CLAFORAN should be given 1/2 or 1 1/2 hours before surgery. See DOSAGE AND ADMINISTRATION section. For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as with a non-absorbable antibiotic (e.g., neomycin) is recommended.

If there are signs of infection, specimens for culture should be obtained for identification of the causative organism so that appropriate therapy may be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLAFORAN and other antibacterial drugs, CLAFORAN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

CONTRAINDICATIONS CLAFORAN is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, or the cephalosporin group of antibiotics.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Adults Dosage and route of administration should be determined by susceptibility of the causative organisms, severity of the infection, and the condition of the patient (see table for dosage guideline). CLAFORAN may be administered intramuscularly (IM) or intravenously (IV) after reconstitution.

The maximum daily dosage should not exceed 12 grams. GUIDELINES FOR DOSAGE OF CLAFORAN Type of Infection Daily Dose Frequency and Route Gonococcal urethritis/ cervicitis in males and females 0.5 gram 0.5 gram IM (single dose) Rectal gonorrhea in females 0.5 gram 0.5 gram IM (single dose) Rectal gonorrhea in males 1 gram 1 gram IM (single dose) Uncomplicated infections 2 grams 1 gram every 12 hours IM or IV Moderate to severe infections 3 to 6 grams 1-2 grams every 8 hours IM or IV Infections commonly needing antibiotics in higher dosage (e.g., septicemia) 6 to 8 grams 2 grams every 6 to 8 hours IV Life-threatening infections up to 12 grams 2 grams every 4 hours IV If C. trachomatis is a suspected pathogen, appropriate anti-chlamydial coverage should be added, because cefotaxime sodium has no activity against this organism.

To prevent postoperative infection in contaminated or potentially contaminated surgery, the recommended dose is a single 1 gram IM or IV administered 30 to 90 minutes prior to start of surgery. Cesarean Section Patients The first dose of 1 gram is administered intravenously as soon as the umbilical cord is clamped. The second and third doses should be given as 1 gram intravenously or intramuscularly at 6 and 12 hours after the first dose.

Pediatric patients The following dosage schedule is recommended: Birth to 7 days of age 50 mg/kg per dose every 12 hours IV 8 days to 28 days of age 50 mg/kg per dose every 8 hours IV It is not necessary to differentiate between premature and normal-gestational age infants. 29 days to 12 years: For body weights less than 50 kg, the recommended daily dose is 50 mg/kg to 180 mg/kg IM or IV body weight divided into four to six equal doses. The higher dosages should be used for more severe or serious infections, including meningitis.

For body weights 50 kg or more, the usual adult dosage should be used; the maximum daily dosage should not exceed 12 grams. Geriatric Use This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

(See PRECAUTIONS, General and PRECAUTIONS, Geriatric Use.) Impaired Renal Function - see PRECAUTIONS, General. NOTE: As with antibiotic therapy in general, administration of CLAFORAN should be continued for a minimum of 48 to 72 hours after the patient defervesces or after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary tract infection and may be required for several months after therapy has been completed; persistent infections may require treatment of several weeks and doses smaller than those indicated above should not be used.

Preparation of CLAFORAN CLAFORAN for IM or IV administration should be reconstituted as follows: Strength Diluent Withdrawable Volume Concentration 1 g per vial* (IM) 3 mL 3.4 mL 300 mg/mL 1 g per vial* (IV) 10 mL 10.4 mL 95 mg/mL (*) in conventional vials Shake to dissolve; inspect for particulate matter and discoloration prior to use. Solutions of CLAFORAN range from colorless to light yellow, depending on concentration, diluent used, and length and condition of storage.

For intramuscular use Reconstitute VIALS with Sterile Water for Injection or Bacteriostatic Water for Injection as described above. For intravenous use Reconstitute VIALS with at least 10 mL of Sterile Water for Injection. For other diluents, see COMPATIBILITY AND STABILITY section. NOTE: Solutions of CLAFORAN must not be admixed with aminoglycoside solutions.

If CLAFORAN and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection. A SOLUTION OF 1 G CLAFORAN IN 14 ML OF STERILE WATER FOR INJECTION IS ISOTONIC. IM Administration As with all IM preparations, CLAFORAN should be injected well within the body of a relatively large muscle such as the upper outer quadrant of the buttock (i.e., gluteus maximus); aspiration is necessary to avoid inadvertent injection into a blood vessel.

Do not administer intramuscular doses of 2 grams at a single injection site. Divide the dose and administer at separate intramuscular sites. IV Administration The IV route is preferable for patients with bacteremia, bacterial septicemia, peritonitis, meningitis, or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or impending.

For intermittent IV administration, a solution containing 1 gram or 2 grams in 10 mL of Sterile Water for Injection can be injected over a period of three to five minutes. Cefotaxime should not be administered over a period of less than three minutes. (See WARNINGS). With an infusion system, it may also be given over a longer period of time through the tubing system by which the patient may be receiving other IV solutions.

However, during infusion of the solution containing CLAFORAN, it is advisable to discontinue temporarily the administration of other solutions at the same site. Compatibility and Stability Solutions of CLAFORAN reconstituted for IM or IV administration as described above (Preparation of CLAFORAN) remain chemically stable (potency remains above 90%) and microbiologically stable as follows when stored in original containers: Strength Reconstituted Concentration Stability at or below 22°C (72°F) Stability under Refrigeration (at or below 5°C (41°F)) Original Containers 1 g per vial (IM) 300 mg/mL 12 hours 7 days 1 g per vial (IV) 95 mg/mL 24 hours 7 days Reconstituted solutions may be further diluted up to 1,000 mL with the following solutions and maintain satisfactory potency and are microbiologically stable for 24 hours at or below 22°C (72°F), and for 5 days under refrigeration (at or below 5°C (41°F)): 0.9% Sodium Chloride Injection; 5% or 10% Dextrose Injection; 5% Dextrose and 0.9% Sodium Chloride Injection, 5% Dextrose and 0.45% Sodium Chloride Injection; 5% Dextrose and 0.2% Sodium Chloride Injection; Lactated Ringers Solution, 8.5% Travasol ® (Amino Acid) Injection without Electrolytes.

NOTE: CLAFORAN solutions exhibit maximum stability in the pH 5-7 range. Solutions of CLAFORAN should not be prepared with diluents having a pH above 7.5, such as Sodium Bicarbonate Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration)

Impaired Renal Function - see PRECAUTIONS, General. NOTE: As with antibiotic therapy in general, administration of CLAFORAN should be continued for a minimum of 48 to 72 hours after the patient defervesces or after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary tract infection and may be required for several months after therapy has been completed; persistent infections may require treatment of several weeks and doses smaller than those indicated above should not be used.

Preparation of CLAFORAN CLAFORAN for IM or IV administration should be reconstituted as follows: Strength Diluent Withdrawable Volume Concentration 1 g per vial* (IM) 3 mL 3.4 mL 300 mg/mL 1 g per vial* (IV) 10 mL 10.4 mL 95 mg/mL (*) in conventional vials Shake to dissolve; inspect for particulate matter and discoloration prior to use. Solutions of CLAFORAN range from colorless to light yellow, depending on concentration, diluent used, and length and condition of storage.

For intramuscular use Reconstitute VIALS with Sterile Water for Injection or Bacteriostatic Water for Injection as described above. For intravenous use Reconstitute VIALS with at least 10 mL of Sterile Water for Injection. For other diluents, see COMPATIBILITY AND STABILITY section. NOTE: Solutions of CLAFORAN must not be admixed with aminoglycoside solutions.

If CLAFORAN and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection. A SOLUTION OF 1 G CLAFORAN IN 14 ML OF STERILE WATER FOR INJECTION IS ISOTONIC. IM Administration As with all IM preparations, CLAFORAN should be injected well within the body of a relatively large muscle such as the upper outer quadrant of the buttock (i.e., gluteus maximus); aspiration is necessary to avoid inadvertent injection into a blood vessel.

Do not administer intramuscular doses of 2 grams at a single injection site. Divide the dose and administer at separate intramuscular sites. IV Administration The IV route is preferable for patients with bacteremia, bacterial septicemia, peritonitis, meningitis, or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or impending.

For intermittent IV administration, a solution containing 1 gram or 2 grams in 10 mL of Sterile Water for Injection can be injected over a period of three to five minutes. Cefotaxime should not be administered over a period of less than three minutes. (See WARNINGS). With an infusion system, it may also be given over a longer period of time through the tubing system by which the patient may be receiving other IV solutions.

However, during infusion of the solution containing CLAFORAN, it is advisable to discontinue temporarily the administration of other solutions at the same site. Compatibility and Stability Solutions of CLAFORAN reconstituted for IM or IV administration as described above (Preparation of CLAFORAN) remain chemically stable (potency remains above 90%) and microbiologically stable as follows when stored in original containers: Strength Reconstituted Concentration Stability at or below 22°C (72°F) Stability under Refrigeration (at or below 5°C (41°F)) Original Containers 1 g per vial (IM) 300 mg/mL 12 hours 7 days 1 g per vial (IV) 95 mg/mL 24 hours 7 days Reconstituted solutions may be further diluted up to 1,000 mL with the following solutions and maintain satisfactory potency and are microbiologically stable for 24 hours at or below 22°C (72°F), and for 5 days under refrigeration (at or below 5°C (41°F)): 0.9% Sodium Chloride Injection; 5% o

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Powder for injection: 1 g, 250 mg, 500 mg, 1000 mg
  • Powder for solution for injection: 1 g

Registered products in the Philippines

72 products registered with the Food and Drug Administration (FDA) Philippines list Cefotaxime as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products72
Philippine FDA-registered products for Cefotaxime
Package insert
AccetaximeCefotaxime (As Sodium)
1 g Powder for Solution for Injection (IM/IV)Type I glass vial with grey butyl rubber stopper and flip off seal x 15 mL (Box of 1's)
Rx
Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan
Importer: Accesspoint International Trading, Inc.
DRP-11654
Apr 7, 2027
AetaximeCefotaxime (as Sodium)
1g Powder for Injection (IV/IM)15 mL capacity low borosilicate clear and colorless glass vial with Bromobutyl Rubber Stopper and Aluminum Seal with Red Flip-off Cap Box of 10 Vials in individual Cartons
Rx
Sinopharm Zhijun (Shenzhen) Pharmaceutical Co., Ltd.China
Dynasty Pharmaceuticals
DRP-8487
Nov 2, 2027
AnzoximCefotaxime (As Sodium)
1 g Powder For Injection (I.M./I.V.)10 mL USP Type III clear glass vial + 5 mL FFS ampoule (Sterile Water for Injection as diluent) (Box of 1's)
Rx
Injectcare Parenterals Pvt. Ltd.India
Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DR-XY 47798
Mar 10, 2027
AtomixCefotaxime (as sodium)
1 g Powder for Injection (I.M./I.V.)USP Type III clear moulded glass vial sealed with grey bromo butyl rubber stopper and dark blue flip-off seal Box of 1's
Rx
Theon Pharmaceuticals LimitedIndia
HEXAGON PHARMACEUTICALS
DR-XY46746
Oct 15, 2029
AusfotaximeCefotaxime (As Sodium)
1g Powder For Injection (IM/IV)10 mL-capacity Type I Borosilicate clear glass vial with dark grey rubber stopper and blue aluminum cap (Box of 10's)
Rx
Union Korea Pharm Co., Ltd.Korea
JLT Pharma Inc.Trader: Auskorea Pharm. Co., Ltd.
DRP-11664
Apr 25, 2027
CeffapixxCefotaxime (as sodium)
500 mg Powder for Injection (IM/IV)10 mL-capacity Type III molded glass vial with grey butyl rubber stopper and blue colour flip-off aluminum seal + 10 mL-net content LDPE plastic ampoule water for injection (Box of 1's)
Rx
Innova Captab LimitedIndia
RSG Mktg Corp.Importer: Ambica International Corporation
DRP-14721-01
Dec 4, 2028
CefogramCefotaxime (as Sodium)
1g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial with Rubber Stopper and Green Flip-off Seal x 1g (Box of 1's)
Rx
FUREN PHARMACEUTICAL GROUP CO., LTD.China
ASIANMEDS, INC.Trader: Shanxi Shuguang Pharmaceutical Co., Ltd
DR-XY37948
May 17, 2028
CefogramCefotaxime (as Sodium)
1g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial with Rubber Stopper and Green Flip-Off Seal x 1g (Box of 1)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Asianmeds, Inc.Trader: Shanxi Shuguang Pharmaceutical Co., Ltd.
DRP-16307
May 17, 2028
CefolanCefotaxime (as Sodium)
1 g Powder for Injection (IM/IV)USP Type III Clear Glass vial with Rubber Stopper and Yellow Flip-off seal x 1 g (Box of 1's)
Rx
ZHUHAI UNITED LABORATORIES (ZHONGSHAN) CO., LTD.China
AGLOBAL CARE, INC.
DRP-8685
Jul 19, 2027
CeforinCefotaxime (as Sodium)
1 g Powder for Injection (I.M./I.V.)USP Type I Clear and colorless glass vial (Box of 1 vial)
Rx
Haikou Pharmaceutical Factory Co., Ltd.China
Endure Medical Inc.
DR-XY45845
Apr 3, 2027
CeforinCefotaxime (as Sodium)
1g Powder for Injection (I.M./I.V.)USP Type I Clear and colorless glass vial (Box of 1 vial)
Rx
Haikou Pharmaceutical Factory Co., Ltd.China
Endure Medical Inc.
DRP-16848
Apr 3, 2027
CefotaxCefotaxime (as Sodium)
1 g Powder for Injection (IM/IV)USP Type II glass vial with light blue flip-off seal
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
—
DR-XY36867
Jan 4, 2029
CefotaxCefotaxime (as sodium)
500 mg Powder for Injection (IM/IV)USP Type I vial with rubber stopper sealed with flip-off aluminium seal x 500 mg (Box of 10's)
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
—
DR-XY37735
Sep 14, 2027
CefotaxsaphCefotaxime
1 g Powder for Solution for Injection (I.M./I.V.)USP Type I Flint Glass Vial with Bromo Butyl rubber stopper and Flip-off Aluminium seal x 10 mL and 10's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-13147
Dec 7, 2027
CefoxinCefotaxime (as sodium)
1 g Powder for Injection (IM/IV)USP Type I Glass Vial (Box of 10's)
Rx
Union Korea Pharm Co., Ltd.Republic of Korea
Delex Pharma International, Inc.Importer: H & B Pharma International Inc.
DRP-1356-02
Nov 20, 2028
CefutazCefotaxime (as hydrochloride)
1 g Powder for Injection (IM/IV)10 mL capacity-USP type II glass vial with rubber stopper and flip-off seal + plastic FFS x 10 mL for sterile water for injection (diluent) (Box of 1's)
Rx
Finebiotics Pharma Ltd.India
Medinova Pharmaceutical Inc.
DRP-16599
May 13, 2030
CetaximaCefotaxime (as Sodium)
1 g Powder for Injection (IM/IV)Vial x 1 g (Box of 10's)
Rx
Yung Shin Pharm. Ind. Co., Ltd. - Taichung Youth Factory IIITaiwan
Yung Shin (Philippines), Inc.
DR-XY21532
Jul 5, 2031
CladexCefotaxime (as Sodium)
1 g Powder for Injection (I.M./I.V.)USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
PT Dexa MedicaIndonesia
Glorious Dexa Mandaya, Inc.
DRP-8137
Sep 25, 2029
CladexCefotaxime (as sodium)
500 mg Powder for Injection (IM/IV)15 mL-capacity USP Type I clear glass vial with rubber stopper and aluminum cap (Box of 1's)
Rx
PT Dexa MedicaIndonesia
Glorious Dexa Mandaya, Inc.
DRP-14566
Oct 16, 2028
EmixonCefotaxime (as sodium)
1g Powder for Injection (IM/IV)10 mL Type III Clear Glass Vial Sealed with Gray Butyl Rubber Stopper and Sky-Blue Aluminum Flip- Off Seal Cap x 1's+ 10 mL Sterile Water for Injection in Type I Clear Glass Ampoule x 1's (Box of 1's)
Rx
Vellinton HealthcareIndia
Pranish, Inc.
DR-XY48865
Sep 4, 2028
EmixonCefotaxime (as sodium)
1g Powder for Injection (IM/IV)10 mL Type III Clear Glass Vial Sealed with Gray Butyl Rubber and Sky-Blue Aluminum Flip-Off Seal Cap x 1's + 10 mL Sterile Water for Injection in Type I Clear Glass Ampoule x 1's (Box of 1's)
Rx
Vellinton HealthcareIndia
Pranish, Inc.
DRP-15864
Sep 4, 2028
Eotax-1000Cefotaxime (as sodium)
1 g Powder for Injection (IM/IV)10 mL- capacity USP Type II clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
Zee Laboratories LimitedIndia
Eon Pharmatek Inc.
DR-XY48526
Dec 14, 2027
FortaximeCefotaxime (as sodium)
1 g Powder for Injection (IM/IV)10 mL-capacity USP Type II clear glass vial with bromobutyl rubber stopper and aluminum seal with blue flip-off cap (Box of 10's)
Rx
Reyoung Pharmaceutical Co., LtdChina
Philgen Pharmaceuticals Inc.
DRP-16421
Mar 5, 2030
FotaxinCefotaxime (As Sodium)
1 g Powder for Injection (I.M./I.V.)USP Type I Glass Vial (Box of 10's)
Rx
Union Korea Pharm Co., Ltd.South Korea
Altomed Pharmaceuticals, Inc.Importer: H & B Pharma International Inc.
DRP-1356
Jun 9, 2031
HaifotaxCefotaxime (as sodium)
1 g Powder for Injection (I.M. / I.V.)10 mL USP Type Ill clear glass vial sealed with grey bromobutyl stopper and 20 mm dark blue color flip-off + 10 mL LDPE ampoule (Sterile Water for Injection as diluent) (Box of 1's)
Rx
Theon Pharmaceuticals LimitedIndia
Triple Tact Import & Export Corp.Importer: Greencore Pharma Inc.
DRP-11481-02
Mar 16, 2027
HaximCefotaxime (as Sodium)
1g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with Rubber Stopper and Blue Flip-off Seal (Box of 10's)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina
Endure Medical, Inc.
DR-XY33532
Jul 6, 2027
HaximCefotaxime (as Sodium)
1g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with Rubber Stopper and Blue Flip-off Seal + 5 mL Ampoule Water for Injection (Box of 1's)
Rx
Harbin Pharmaceutical Group Co. Ltd. General Pharm. FactoryChina
Endure Medical, Inc.
DR-XY34646
Jun 25, 2028
HaximCefotaxime (as Sodium)
1g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with Rubber Stopper and Blue Flip-off Seal (Box of 10's)
Rx
Endure Medical, Inc.Philippines
Endure Medical, Inc.
DRP-16348
Jul 6, 2027
HaximCefotaxime (as Sodium)
1g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with Rubber Stopper and Blue Flip-off Seal + 5 mL Ampoule Water for Injection (Box of 1's)
Rx
Harbin Pharmaceutical Group Co. Ltd. General Pharm. FactoryChina
Endure Medical, Inc.
DRP-16539
Jun 25, 2028
HaximCefotaxime (as sodium)
500mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial with Rubber Stopper and Blue Flip-Off Seal (Box of 10's)
Rx
Harbin Pharmaceutical Group Co., Ltd General Pharm. FactoryChina
Endure Medical, Inc.
DR-XY33529
Jul 6, 2027
HaximCefotaxime (as sodium)
500mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial with Rubber Stopper and Blue Flip-Off Seal (Box of 10's)
Rx
Harbin Pharmaceutical Group Co., Ltd General Pharm. FactoryChina
Endure Medical, Inc.
DRP-16347
Jul 6, 2027
KelximeCefotaxime (As Sodium)
1g Powder For Injection (I.M./I.V.)10 mL USP Type III clear glass vial sealed with grey bromobutyl stopper and 20 mm dark blue color flip-off + 10 mL LDPE ampoule (Sterile Water for Injection as diluent) Box of 1's)
Rx
Theon Pharmaceuticals LimitedIndia
Importer: Greencore Pharma Inc.
DRP-11481
Mar 16, 2027
LuotaximeCefotaxime (as sodium)
1 g Powder for Injection (IM/IV)10 mL-capacity soda-lime glass vial with rubber stopper and aluminum plastic cap (Box of 1's and 10's)
Rx
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.China
Luoxin Pharmaceuticals (PH) Corp.
DR-XY49151
Jul 31, 2029
MedzidimeCefotaxime (As Sodium)
1 g Powder For Injection (Im/Iv)10 mL Type III Glass Vial with Gray Bromobutyl Rubber Stopper and Sealed with Aluminum Seal Cap x 1's (Box of 1's)
Rx
Ananta Medicare LimitedIndia
Medinova Pharmaceutical, Inc.
DRP-14202
Jul 18, 2028
MirutaximCefotaxime (as Sodium)
1 g Powder for Injection (IV/IM)10 mL-net content USP Type III glass vial with rubber stopper, flip-off seal and blue cap (Box of 1's)
Rx
MAKCUR LABORATORIES LIMITEDIndia
Penta Labs Australia (Philippines)Trader: U SQUARE LIFESCIENCE PVT. LTD.
DRP-15889
Sep 27, 2029
NexatineCefotaxime (as sodium)
1 g Powder for Injection (IM/IV)10 mL-capacity, USP Type III clear glass vial with rubber stopper and sky blue aluminum flip-off seal (Box of 1's)
Rx
Vellinton HealthcareIndia
Pranish Inc.
DR-XY48901
Oct 16, 2028
NexatineCefotaxime (as sodium)
1 g Powder for Injection (IM/IV)10 mL- capacity, USP Type III clear glass vial with rubber stopper and sky blue aluminum flip-off seal (Box of 1's)
Rx
Vellinton HealthcareIndia
Pranish Inc.
DRP-14990
Oct 16, 2028
NoneCefotaxime (as sodium)
1 g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial with Rubber Stopper and Red Flip-Off Seal + 5 mL Ampoule (Diluent) (Box of 1's)
Rx
Bosch Pharmaceutical (Pvt.) Ltd.Pakistan
Nueva Sunshine Phils., Inc.Importer: Sahar International Trading Inc.
DRP-13817-01
Oct 15, 2028
NoneCefotaxime (as Sodium)
1g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with Rubber Stopper and Blue Flip-off Seal (Box of 10's)
Rx
Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina
Phil Pharmawealth, Inc.Importer: Endure Medical, Inc.
DRP-16348-01
Jul 6, 2027
NoneCefotaxime (as Sodium)
250 mg Powder for Injection (I.M./I.V.)Clear Glass Vial w/ Rubber Stopper and Blue Flip-off Seal (Box of 1's and 10's)
Rx
Karnataka Antibiotics & Pharma Ltd.India
Phil Pharmawealth, Inc.
DR-XY27363
Mar 15, 2027
NoneCefotaxime (as Sodium)
500 mg Powder for Injection (I.M./I.V.)Glass vial w/ rubber stopper and blue flip off seal Box of 10's
Rx
Karnataka Antibiotics & Pharmaceuticals Ltd.India
Phil. Pharmawealth, Inc.
DR-XY27683
Jul 12, 2027
NoneCefotaxime (as sodium)
500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial with Rubber Stopper and Blue Flip- Off Seal (Box of 10's)
Rx
Harbin Pharmaceutical Group Co., Ltd General Pharm. FactoryChina
Phil Pharmawealth, Inc.Importer: Endure Medical, Inc.
DRP-16347-01
Jul 6, 2027
One-CefotaxcelCefotaxime (As Sodium)
1 g Powder For Injection (IM/IV)10 mL-capacity USP Type I clear glass vial with gray bromobutyl rubber stopper and aluminum flip-off seal (Box of 1’s)
Rx
Swiss Parenterals Ltd.India
One Dexcel Pharma Inc.
DRP-12196
Jul 1, 2027
OximaCefotaxime (as Sodium)
1 g Powder for Injection (IM/IV)Type III Clear Colorless Glass Vial with Grey Butyl Rubber Stopper and Sealed with Blue Flip-off Aluminum Cap (Box of 1’s and 10’s)
Rx
NCPC Hebei Huamin Pharmaceutical Company LimitedChina
Bellus Life Solutions, Inc.Importer: Aglobal Care, Inc.
DRP-8686-01
May 18, 2028
Phil CefotamCefotaxime (as sodium)
1 g Powder for InjectionUSP Type I Clear Glass Vial (Box of 10's)
Rx
Samchundang Pharm. Co. Ltd.Republic of Korea
Bliss Pharma Distribution and Consultancy Corp.
DR-XY41595
Jan 25, 2028
ProtaximCefotaxime (as sodium)
1 g Powder for Injection (IM/IV)10 mL capacity USP Type III clear glass vial with rubber stopper and aluminum blue flip-off cap (Box of 1's)
Rx
Sance Laboratories Pvt. LtdIndia
Greencore Pharma Inc.
DRP-15554
Jul 31, 2029
Protaxim 500.Cefotaxime (as sodium)
500 mg Powder for Injection (IM/IV)10 mL capacity USP Type III clear glass vial with rubber stopper and aluminum blue flip-off cap (Box of 1's)
Rx
Sance Laboratories Pvt. LtdIndia
Greencore Pharma Inc.
DRP-15553
Jul 31, 2029
QuximeCefotaxime (as sodium)
1g Powder for Injection (I.M./I. V .)10 mL USP Type Ill clear glass vial sealed with grey bromobutyl stopper and 20 mm dark blue color flip-off + 10 mL LDPE ampoule (Sterile Water for Injection as diluent) (Box of 1's)
Rx
Theon Pharmaceuticals LimitedIndia
Ellebasy Medicale Group Inc.Importer: Greencore Pharma Inc.
DRP-11481-01
Mar 16, 2027
RafoximeCefotaxime Sodium
1000 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial x 10 mL sealed with Rubber Stopper and Flip-off Seal Packed in a Carton with Plastic Tray with Diluent (Sterile Water for Injection) x 5 mL (Box of 1's & 10's)
Rx
Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd.China
Raquel-Abbas Pharma Inc.
DRP-18592
Sep 7, 2031
RaroximeCefotaxime (as sodium)
1 g Powder for Injection (IV/IM)USP Type I Glass Vial (Box of 10's)
Rx
Phil Inter Pharma Co., Ltd.Vietnam
GPC Geo Pharma Corporation
DRP-6826
Apr 11, 2028
RetaxCefotaxime (As Sodium)
1g Powder For Injection (IM/IV)10 mL-capacity USP Type II glass vial with butyl rubber stopper and aluminum flip-off cap (Box of 10 vials in plastic tray)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Pharma-Surrey International, Inc.
DRP-11663
Apr 25, 2027
RycefoxCefotaxime (as sodium)
500 mg Powder for Injection (IM/IV)10 mL-capacity Type III molded glass vial with grey butyl rubber stopper and blue colour flip-off aluminum seal + 10 mL-net content LDPE plastic ampoule water for injection (Box of 1's)
Rx
Innova Captab Ltd.India
Tamiga Pharmaceuticals SupplyImporter: Ambica International Corporation
DRP-14721-02
Dec 4, 2028
SefoxCefotaxime (as Sodium)
1 g Powder for Injection (IM/IV)Type III Clear Colorless Glass Vial with Grey Butyl Rubber Stopper and Sealed with Blue Flip-off Aluminum Cap (Box of 1’s and 10’s)
Rx
NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China
AGLOBAL CARE, INC.
DRP-8686
May 18, 2028
SITICEFCefotaxime (as sodium)
1 g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial with Rubber Stopper and Red Flip-Off Seal + 5 mL Ampoule (Diluent) (Box of 1's)
Rx
Bosch Pharmaceutical (Pvt.) Ltd.Pakistan
Sahar International Trading Inc.
DRP-13817
Oct 15, 2028
SitiximeCefotaxime (As sodium)
1 g Powder For Injection (IM/IV)10 mL-Capacity USP Type I Clear and Colorless Glass Vial with Butyl Rubber Stopper and Aluminum Seal with Blue-colored Plastic Flip-Off Cap (Box of 1's)
Rx
Zhuhai Kinhoo Pharmaceutical Co., Ltd.China
Sahar International Trading, Inc.Trader: Betterway Pharmaceutical Group (HK) Limited
DR-XY47815
Mar 15, 2027
TacsenzCefotaxime (as sodium)
1 g Powder for Injection (I.M./I.V.)USP Type I Glass Vial (Box of 10's)
Rx
Union Korea Pharm Co., Ltd.Republic of Korea
Pharmaessence Inc.Importer: H & B Pharma International Inc.
DRP-1356-03
Nov 20, 2028
TergenCefotaxime (as sodium)
1 g Powder for Injection (IM/IV)10 mL-capacity Type III transparent glass vial sealed with grey butyl rubber stopper and aluminum plastic cap (Box of 10 individually packed vials)
Rx
NCPC Hebei Huamin Pharmaceutical Company LimitedChina
Southmed Pharma CorporationImporter: AMB HK Enterprises Inc.
DRP-9054-01
Sep 19, 2031
TergenCefotaxime (as sodium)
500 mg Powder for Injection (IM/IV)10mL Capacity-Type III Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with PP Flip-Off Cap x 1's (Box of 1's and 10's)
Rx
NCPC Hebei Huamin Pharmaceutical Company LimitedChina
Southmed Pharma CorporationImporter: AMB HK Enterprises Inc.
DRP-16960-01
Sep 2, 2030
TerrafoxCefotaxime (as hydrochloride)
1 g Powder for Injection (IM/IV)10 mL capacity-USP Type II glass vial with rubber stopper and flip-off seal + plastic FFS x 10 mL for sterile water for injection (diluent) (Box of 1's)
Rx
Finebiotics Pharma Ltd.India
Santerra TradingImporter: Medinova Pharmaceutical Inc.
DRP-16599-01
May 13, 2030
ToximCefotaxime (as sodium)
1 g Powder for Injection (IM/IV)10 mL-capacity Type III transparent glass vial sealed with grey butyl rubber stopper and aluminum plastic cap (Box of 10 individually packed vials)
Rx
NCPC Hebei Huamin Pharmaceutical Company LimitedChina
AMB HK Enterprises Inc.
DRP-9054
Oct 31, 2030
Toxim 500Cefotaxime (as sodium)
500 mg Powder for Injection (IM/IV)10mL Capacity-Type III Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with PP Flip-Off Cap x 1's (Box of 1's and 10's)
Rx
NCPC Hebei Huamin LimitedChina
AMB HK Enterprises Inc.
DRP-16960
Sep 2, 2030
TrenchCefotaxime (as sodium)
1 g Powder for Injection (IM/IV)15 mL-capacity glass vial with rubber stopper and red aluminum flip-off seal (Box of 1's)
Rx
Hansel Pharmaceuticals (Pvt.) Ltd.Pakistan
Zuneca Incorporated
DRP-14565
Oct 16, 2028
UnbrandedCefotaxime (as Sodium)
1 g Powder for Injection (I.M./I.V.)1 g Clear Glass Vial with rubber stopper and blue flip-off seal (Box of 10's)
Rx
Karnataka Antibiotics & Pharmaceuticals LimitedIndia
Phil. Pharmawealth, Inc.
DR-XY27364
Mar 15, 2032
Vivaxime 500Cefotaxime (As Sodium)
500 mg Powder For Injection (IM/IV)10 mL USP type II glass mould vial with flip-off cap (Box of 10's and 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
KDSJ Pharma Inc.
DRP-11416
Mar 11, 2027
XimvexCefotaxime (as Sodium)
1g Powder for Injection (IM/IV)USP Type I clear and colorless glass vial with green-colored flip-off seal + USP Type I clear and colorless glass ampoule x 10 mL Sterile Water for Injection as diluent Box of 1's
Rx
North China Pharmaceutical Co., Ltd.China
Sannovex Pharmaceutical Distributor
DRP-6458
Dec 17, 2030
ZefcefoxCefotaxime (as sodium)
1 g Powder for Injection (IM/IV)10 mL-capacity Type III molded glass vial with grey butyl rubber stopper and blue colour flip-off aluminum seal 10 mL-net content LDPE plastic ampoule water for injection (Box of 1's)
Rx
Innova Captab LimitedIndia
Ambica International Corporation
DRP-14720
Dec 4, 2028
ZefcefoxCefotaxime (as Sodium)
500 mg Powder For Injection (IM/IV)10 mL-capacity Type III molded glass vial with grey butyl rubber stopper and blue colour flip -off aluminum seal + 10 mL-net content LDPE plastic ampoule sterile water for injection (Box of 1’s)
Rx
Innova Captab LimitedIndia
Ambica International Corporation
DRP-14721
Dec 4, 2028
ZefocentCefotaxime (as Sodium)
1 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with rubber stopper and blue flip-off seal (Box of 10’s)
Rx
Samjin Pharmaceutical Co., Ltd.Republic of Korea
Unimex, Inc.
DR-XY29554
Apr 27, 2027
ZefotaxCefotaxime (as sodium)
1 g Powder for Injection (I.M./I.V.)USP Type I Glass Vial (Box of 10's)
Rx
Union Korea Pharm Co., Ltd.Republic of Korea
Zyre Pharmaceuticals CorporationImporter: H & B Pharma International Inc.
DRP-1356-01
Nov 20, 2028
ZentroCefotaxime (as sodium)
1 g Powder for Injection (IM/IV)USP Type I Glass Vial + 5 mL Water for Injection Ampoule as diluent (Box of 1's)
Rx
Goefmann PharmaceuticalsPakistan
Sahar International Trading Inc.
DR-XY39710
Jul 30, 2031
(no brand name)Cefotaxime (as sodium)
1g Powder For Injection (IM/IV)10 mL-capacity USP Type II Glass Vial with bromobutyl rubber stopper (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Incorporated
DRP-14419
Sep 4, 2028
(no brand name)Cefotaxime (as sodium)
1g Powder For Injection (IM/IV)In a box, 10 mL-capacity USP Type II Glass Vial with bromobutyl rubber stopper and aluminum plastic cap and USP Type I glass ampoule x 10 mL (Sterile Water for Injection as diluent)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Incorporated
DRP-14420
Sep 4, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS BEFORE THERAPY WITH CLAFORAN IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFOTAXIME SODIUM, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN WITH CAUTION TO PATIENTS WITH TYPE I HYPERSENSITIVITY REACTIONS TO PENICILLIN.

ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF ALLERGY, PARTICULARLY TO DRUGS. IF AN ALLERGIC REACTION TO CLAFORAN OCCURS, DISCONTINUE TREATMENT WITH THE DRUG. SERIOUS HYPERSENSITIVITY REACTIONS MAY REQUIRE EPINEPHRINE AND OTHER EMERGENCY MEASURES. During post-marketing surveillance, a potentially life-threatening arrhythmia was reported in each of six patients who received a rapid (less than 60 seconds) bolus injection of cefotaxime through a central venous catheter.

Therefore, cefotaxime should only be administered as instructed in the DOSAGE AND ADMINISTRATION section. Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLAFORAN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Clinical Trials Experience CLAFORAN is generally well tolerated. The most common adverse reactions have been local reactions following IM or IV injection. Other adverse reactions have been encountered infrequently. The most frequent adverse reactions (greater than 1%) are: Local (4.3%) - Injection site inflammation with IV administration.

Pain, induration, and tenderness after IM injection. Hypersensitivity (2.4%) - Rash, pruritus, fever, eosinophilia. Gastrointestinal (1.4%) - Colitis, diarrhea, nausea, and vomiting. Symptoms of pseudomembranous colitis can appear during or after antibiotic treatment. Nausea and vomiting have been reported rarely. Less frequent adverse reactions (less than 1%) are: Hematologic System - Neutropenia, leukopenia, have been reported.

Some individuals have developed positive direct Coombs Tests during treatment with CLAFORAN and other cephalosporin antibiotics. Genitourinary System - Moniliasis, vaginitis. Central Nervous System - Headache. Liver - Transient elevations in AST, ALT, serum LDH, and serum alkaline phosphatase levels have been reported. Kidney - As with some other cephalosporins, transient elevations of BUN have been occasionally observed with CLAFORAN.

Post-Marketing Experience The following adverse reactions have been identified during post-approval use of CLAFORAN. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular System - Potentially life-threatening arrhythmias following rapid (less than 60 seconds) bolus administration via central venous catheter have been observed.

Central Nervous System - Administration of high doses of beta-lactam antibiotics, including cefotaxime, particularly in patients with renal insufficiency may result in encephalopathy (e.g. impairment of consciousness, abnormal movements and convulsions). Dizziness has also been reported. Cutaneous - As with other cephalosporins, isolated cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have been reported.

Acute generalized exanthematous pustulosis (AGEP) has also been reported. General disorders and administration site conditions - Inflammatory reactions at the injection site, including phlebitis/thrombophlebitis. Hematologic System - Hemolytic anemia, agranulocytosis, thrombocytopenia, pancytopenia, bone marrow failure. Hypersensitivity - Anaphylaxis (e.g., angioedema, bronchospasm, malaise possibly culminating in shock), urticaria.

Kidney - Interstitial nephritis, transient elevations of creatinine, acute renal failure. Liver - Hepatitis, jaundice, cholestasis, elevations of gamma GT and bilirubin. Cephalosporin Class Labeling In addition to the adverse reactions listed above which have been observed in patients treated with cefotaxime sodium, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics: allergic reactions, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage, and false-positive test for urinary glucose.

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. See DOSAGE AND ADMINISTRATION and OVERDOSAGE. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

CLINICAL PHARMACOLOGY Following intramuscular (IM) administration of a single 500 mg or 1 g dose of CLAFORAN to normal volunteers, mean peak serum concentrations of 11.7 and 20.5 mcg/mL respectively were attained within 30 minutes and declined with an elimination half-life of approximately 1 hour.

There was a dose-dependent increase in serum levels after the intravenous (IV) administration of 500 mg, 1 g, and 2 g of CLAFORAN (38.9, 101.7, and 214.4 mcg/mL respectively) without alteration in the elimination half-life.

There is no evidence of accumulation following repetitive IV infusion of 1 g doses every 6 hours for 14 days as there are no alterations of serum or renal clearance.

Approximately 20-36% of an intravenously administered dose of 14 C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite.

Two other urinary metabolites (M 2 and M 3 ) account for about 20-25%.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Following intramuscular (IM) administration of a single 500 mg or 1 g dose of CLAFORAN to normal volunteers, mean peak serum concentrations of 11.7 and 20.5 mcg/mL respectively were attained within 30 minutes and declined with an elimination half-life of approximately 1 hour. There was a dose-dependent increase in serum levels after the intravenous (IV) administration of 500 mg, 1 g, and 2 g of CLAFORAN (38.9, 101.7, and 214.4 mcg/mL respectively) without alteration in the elimination half-life.

There is no evidence of accumulation following repetitive IV infusion of 1 g doses every 6 hours for 14 days as there are no alterations of serum or renal clearance. About 60% of the administered dose was recovered from urine during the first 6 hours following the start of the infusion. Approximately 20-36% of an intravenously administered dose of 14 C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite.

The desacetyl metabolite has been shown to contribute to the bactericidal activity. Two other urinary metabolites (M 2 and M 3) account for about 20-25%. They lack bactericidal activity. A single 50 mg/kg dose of CLAFORAN was administered as an intravenous infusion over a 10- to 15- minute period to 29 newborn infants grouped according to birth weight and age.

The mean half-life of cefotaxime in infants with lower birth weights (< 1500 grams), regardless of age, was longer (4.6 hours) than the mean half-life (3.4 hours) in infants whose birth weight was greater than 1500 grams. Mean serum clearance was also smaller in the lower birth weight infants. Although the differences in mean half- life values are statistically significant for weight, they are not clinically important.

Therefore, dosage should be based solely on age. (See DOSAGE AND ADMINISTRATION section.) Drug Interactions A single intravenous dose and oral dose of probenecid (500 mg each) followed by two oral doses of probenecid 500 mg at approximately hourly intervals administered to three healthy male subjects receiving a continuous infusion of cefotaxime increased the steady-state plasma concentration of cefotaxime by approximately 80%.

In another study, administration of oral probenecid 500 mg every 6 hours to six healthy male subjects with cefotaxime 1 gram infused over 5 minutes decreased the total clearance of cefotaxime by approximately 50%. Additionally, no disulfiram-like reactions were reported in a study conducted in 22 healthy volunteers administered CLAFORAN and ethanol.

Microbiology Mechanism of Action Cefotaxime sodium is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefotaxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Resistance Resistance to cefotaxime is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability.

Antimicrobial Activity Susceptibility to cefotaxime will vary geographically and may change over time; local susceptibility data should be consulted, if available. Cefotaxime has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section: Gram-positive bacteria Enterococcus spp. 1 Staphylococcus aureus (methicillin-susceptible isolates only) Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus pyogenes (Group A beta-hemolytic streptococci) Streptococcus spp.

(Viridans group streptococci) Gram-negative bacteria Acinetobacter spp. Citrobacter spp. 2 Enterobacter spp. 2 Escherichia coli 2 Haemophilus influenzae Haemophilus parainfluenzae Klebsiella spp. (including Klebsiella pneumoniae) 2 Morganella morganii 2 Neisseria gonorrhoeae Neisseria meningitidis Proteus mirabilis 2 Proteus vulgaris 2 Providencia rettgeri 2 Providencia stuartii 2 Serratia marcescens 2 1 Enterococcus species may be intrinsically resistant to cefotaxime. 2 Most extended spectrum beta-lactamase (ESBL)-producing and carbapenemase-producing isolates are resistant to cefotaxime.

Anaerobic bacteria Bacteroides spp., including some isolates of Bacteroides fragilis Clostridium spp. (most isolates of Clostridium difficile are resistant) Fusobacterium spp. (including F usobacterium nucleatum) Peptococcus spp. Peptostreptococcus spp. The following in vitro data are available, but their clinical significance is unknown.

At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefotaxime against isolates of similar genus or organism group. However, the efficacy of cefotaxime in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.

Gram-negative bacteria Providencia spp. Salmonella spp. (including Salmonella typhi) Shigella spp. Susceptibility Testing For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see https://www.fda.gov/STIC.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Cefotaxime 500 mg + 2 mL diluent Vial₱42.33–₱737.44Reference ₱48.77per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Cefotaxime (as sodium salt)
PNF listingInj.: 250 mg vial + 2 mL diluent (IM, IV) 500 mg vial + 2 mL diluent (IM, IV)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. CLAFORAN · SteriMax Inc. [US FDA-approved label, version 2, August 14, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=434fb630-c8d6-4583-b3ee-8e4ba6552c3d
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .